Through a combination of technology and deep-rooted expertise, Allucent offers transformative, efficiency-driven pharmacovigilance (PV) solutions to our partners, across clinical, expanded access and the entire post-marketing lifecycle.
By leveraging expertise across PV, medical, regulatory, clinical, and quality to provide comprehensive and innovative patient safety solutions from clinical to commercialization Allucent forges long-lasting relationships as our customer’s full-service PV provider.
Our safety systems include the latest innovations in technology, combining efficiency, global compliance and complete oversight and access to your safety data. Our systems experts can seamlessly consolidate your safety data allowing you to immediately benefit from industry-leading technology.
Emphasizing efficiency, quality and compliance, in a flexible partnership model, Allucent delivers operational excellence through highly agile PV operations, comprehensive safety surveillance and risk management solutions, global QPPV and local affiliate services, and technical PV consulting including global PV audit strategy development and execution.
Clinical Trial Safety
Allucent provides flexible, global solutions that streamline clinical safety operations at the study or portfolio level in a pharmacovigilance partnership model. Leveraging the latest technology advancements in combination with deep expertise, enhances pharmacovigilance efficiency, providing high quality, complete safety oversight.
Post-Marketing Pharmacovigilance
Our global, post-marketing solutions combine integrated expertise across pharmacovigilance, medical, regulatory, and clinical with technology-driven efficiencies. We offer pharmacovigilance (PV) system set-up and lifecycle maintenance, comprehensive safety surveillance and risk management, global QPPV and local affiliate PV services, and technical PV consulting, including global PV audit strategy and development.
Allucent combines technology innovation with deep expertise to enable our partners to efficiently meet their clinical and post-marketing patient safety obligations
IAN KOVACS
GLOBAL HEAD OF PHARMACOVIGILANCE
